'Better every quarter': Bayer CEO stays course on turnaround plan as pharma sales underwhelm in Q2

With Bayer’s pharma sales growth lagging behind its crop science and consumer health divisions in the second quarter, analysts once again raised the possibility of major changes to the German congl | With Bayer’s pharma sales growth lagging behind its crop science and consumer health divisions in the second quarter, analysts once again raised the possibility of major changes to the German conglomerate’s group structure.